Is systemic anti-cancer therapy neurotoxic? Does chemo brain exist? and should we rename it?

Advances in Experimental Medicine and Biology

Volumn 678, Issue , 2010, Pages 86-95

  Taillibert, Sophie ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN; CARMUSTINE; CATECHOL METHYLTRANSFERASE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; FLUOROURACIL; IFOSFAMIDE; INTERLEUKIN 6; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; SUPEROXIDE DISMUTASE; TAMOXIFEN; THIOTEPA; TUMOR NECROSIS FACTOR ALPHA; XRCC1 PROTEIN; NEUROTOXIN;

AMNESIA; ATTENTION DEFICIT DISORDER; BRAIN FUNCTION; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CLINICAL FEATURE; COGNITIVE DEFECT; DIFFUSION TENSOR IMAGING; DISEASE DURATION; DISTRESS SYNDROME; DRUG DOSE REGIMEN; ELECTROPHYSIOLOGY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENETIC POLYMORPHISM; HUMAN; INTERLEUKIN 6 GENE; MENTAL PERFORMANCE; NEUROIMAGING; NEUROTOXICITY; NONHUMAN; ONCOGENE; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SELF REPORT; SURVIVAL RATE; SYSTEMIC THERAPY; VERBAL MEMORY; VISUAL MEMORY; CHEMICALLY INDUCED DISORDER; NOMENCLATURE; TOXICITY AND INTOXICATION;

ANTINEOPLASTIC AGENTS; COGNITION DISORDERS; HUMANS; NEUROTOXICITY SYNDROMES; NEUROTOXINS; TERMINOLOGY AS TOPIC;

EID: 77956620766     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-6306-2_12     Document Type: Review

References (77)

1. Shilling V, Jenkins V. Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. Eur J Oncol Nurs 2007; 11:6-15.
2. Wieneke MH, Dienst ER. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psychooncology 1995; 4:61-66. (Pubitemid 26093776)
3. van Dam FS, Schagen SB, Muller MJ et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998; 90:210-218. (Pubitemid 28114539)
4. Schagen SB, van Dam FS, Muller MJ et al. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 1999; 85:640-50. (Pubitemid 29075285)
5. Brezden CB, Phillips KA, Abdolell M et al. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2000; 18:2695-701. (Pubitemid 30463551)
6. Ahles TA, Saykin AJ, Furstenberg CT et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 2002; 20:485-93. (Pubitemid 34072533)
7. O'Shaughnessy JA. Effects of epoetin alfa on cognitive function, mood, asthenia and quality of life in women with breast cancer undergoing adjuvant chemotherapy. Clin Breast Cancer 2002; 3(Suppl 3): S116-S120.
8. Tchen N, Juffs HG, Downie FP et al. Cognitive function, fatigue and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol 2003; 21:4175-83. (Pubitemid 46606186)
9. Tannock IF, Ahles TA, Ganz PA et al. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 2004; 22:2233-2239. (Pubitemid 41095159)
10. Castellon SA, Ganz PA, Bower JE et al. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 2004; 26:955-969. (Pubitemid 39577316)
11. Scherwath A, Mehnart A, Schleimer B et al. Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects. Ann Oncol 2006; 17:415-423. (Pubitemid 43329577)
12. Quesnel C, Savard J, Ivers H. Cognitive impairments associated with breast cancer treatments: results from a longitudinal study. Breast Cancer Res Treat 2009; 116(1):113-23.
13. Whitney KA, Lysaker PH, Steiner AR et al. Is 'chemobrain' a transient state? A progressive pilot study among persons with nonsmall cell lung cancer. J Support Oncol 2008; 6(7):313-21.
14. Bender CM, Sereika SM, Berga SL et al. Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncology 2006; 15:422-430. (Pubitemid 43826855)
15. Silverman DH, Dy CJ, Castellon SA et al. Altered frontocortical, cerebellar and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res Treat 2007; 103:303-311. (Pubitemid 46944511)
16. Inagaki M, Yoshikawa E, Matsuoka Y et al. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer 2007; 109:146-156. (Pubitemid 46120202)
17. Saykin AJ, Ahles TA, McDonald BC. Mechanisms of chemotherapy induced cognitive disorders: neuropsychological, pathophysiological and neuroimaging perspectives. Semin Clin Neuropsychiatry 2006; 8:201-216. (Pubitemid 37474731)
18. Collins B, Mackenzie J, Stewart A et al. Cognitive effects of chemotherapy in postmenopausal breast cancer patients 1 year after treatment. Psychooncology 2009; 18:134-143.
19. Wefel JS, Lenzi R, Theriault RL et al. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 2004; 100:2292-9. (Pubitemid 38657875)
20. Wefel JS, Lenzi R, Theriault R et al. 'Chemobrain' in breast carcinoma?: a prologue. Cancer 2004; 101:466-75.
21. Shilling V, Jenkins V, Trapala IS. The (mis)classification of chemo-fog methodological inconsistencies in the investigation of cognitive impairment after chemotherapy. Breast Cancer Res Treat 2006; 95:125-129.
22. Hurria A, Rosen C, Hudis C et al. Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. J Am Geriatr Soc 2006; 54:925-31. (Pubitemid 43847029)
23. Hermelink K, Untch M, Lux MP et al. Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer 2007; 109:1905-1913. (Pubitemid 46668557)
24. Maki P, Hogervorst E. HRT and cognitive decline. Best Pract Res Clin Endocrinol 2003; 17:105-122.
25. Bender CM, Paraska KK, Sereika SM et al. Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: a critical review. J Pain Symptom Manag 2001; 21:407-424. (Pubitemid 32452141)
26. Sherwin BB. Estrogen and cognitive functioning in women. Endocr Rev 2003; 24:133-151. (Pubitemid 36515282)
27. Sherwin BB. Estrogen and memory in women: how can we reconcile the findings? Horm Behav 2005; 47:371-375. (Pubitemid 40222746)
28. Shilling V, Jenkins V, Fallowfield L et al. The effects of oestogens and anti-oestrogens on cognition. Breast 2001; 10:484-491.
29. Asthana S. Estrogen and cognition: the story so far. J Gerontol 2003; 4:322-323. (Pubitemid 36397049)
30. McEwen BS. Estrogen action throughout the brain. Recent Prog Horm Res 2002; 57:357-384.
31. Bender CM, Sereika SM, Brufsky AM et al. Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause 2007; 14:995-998. (Pubitemid 350098658)
32. Collins B, Mackenzie J, Stewart A et al. Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study. Psycho-Oncology 2008. [Epub ahead of print]
33. Jenkins V, Shilling V, Deutsch G et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer 2006; 94:828-34.
34. Stewart A, Collins B, Mackenzie J et al. The cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective study. Psycho-Oncology 2008; 17:122-130. (Pubitemid 351279862)
35. Maki PM, Zonderman AB, Resnick SM. Enhanced verbal memory in non demented elderly women receiving hormone-replacement therapy. Am J Psychiatry 2001; 158:227-233. (Pubitemid 32116520)
36. Wolf OT, Kudielka BM, Hellhammer DH et al. Two weeks of transdermal estradiol treatment in postmenopausal elderly women and its effect on memory and mood: verbal memory changes are associated with the treatment induced estradiol levels. Psychoneuroendocrino 1999; 24:727-741. (Pubitemid 29378500)
37. Jenkins V, Shilling V, Fallowfield L et al. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psycho-Oncology 2004; 13:61-66. (Pubitemid 38139358)
38. Shilling V, Jenkins V, Fallowfield L et al. The effects of hormone therapy on cognition in breast cancer. J Steroid Biochem Mol Biol 2003; 86:405-412. (Pubitemid 37412579)
39. Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 2007; 7:192-201.
40. Vardy J, Wefel JS, Ahles T et al. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol 2008; 19:623-629. (Pubitemid 351461030)
41. Ahles TA, Saykin AJ, Noll WW et al. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology 2003; 12:612-619. (Pubitemid 37086736)
42. Maier SF. Bi-directional immune-brain communication: Implications for understanding stress, pain and cognition. Brain Behav Immun 2003; 17:69-85. (Pubitemid 36369416)
43. Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 2005; 104:788-793. (Pubitemid 41113679)
44. Capuron L, Gumnick JF, Musselman DL et al. Neurobehavioral effects of interferon-alpha in cancer patients: Phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002; 26:643-652. (Pubitemid 34260983)
45. Capuron L, Ravaud A, Dantzer R. Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-alpha treatments in cancer patients. Psychosom Med 2001; 63:376-386. (Pubitemid 32467112)
46. Meyers CA, Yung WK. Delayed neurotoxicity of intraventricular interleukin-2: A case report. J Neurooncol 1993; 15:265-267. (Pubitemid 23182719)
47. Meyers CA, Scheibel RS, Forman AD. Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 1991; 41:672-676.
48. Dietrich J, Han R, Yang Y et al. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and vivo. J Biol 2006; 5:1-23.
49. Rzeski W, Pruskil S, Macke A et al. Anticancer agents are potent neurotoxins in vitro and in vivo. Ann Neurol 2004; 56:351-360. (Pubitemid 39166554)
50. Han R, Yang YM, Dietrich J et al. Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. J Biol 2008; 7:12.
51. Mustafa S, Walker A, bennett G et al. 5-Fluorouracil chemotherapy affects spatial working memory and newborn neurons in the adult rat hippocampus. Eur J Neurisci 2008; 28(2):323-30.
52. Winocur G, Vardy J, Binns MA et al. The effects of the anti-cancer drugs, methotrexate and 5-fluorouracil, on cognitive function in mice. Pharmacol Biochem Behav 2006; 85:66-75. (Pubitemid 44802737)
53. Reiriz AB, Reolon GK, Preissler T et al. Cancer chemotherapy and cognitive function in rodent models: memory impairment induced by cyclophosphamide in mice. Clin Cancer Res 2006; 12:5000 author reply 5000-5001.
54. Macleod JE, Deleo JA, Hickey WF et al. Cancer chemotherapy impairs contextual but not cue-specific fear memory. Behav Brain Res 2007; 181:168-172. (Pubitemid 46765012)
55. Seigers R, Schagen SB, Beerling W et al. Long-lasting suppression of hippocampal cell proliferation and impaired cognitive performance by methotrexate in the rat. Behav Brain Res 2008; 186(2):168-75. (Pubitemid 350122748)
56. Tangpong J, Cole MP, Sultana R et al. Adriamycin-mediated nitration of manganese superoxide dismutase in the central nervous system: insight into the mechanism of chemobrain. Journal of Neurochemistry 2007; 100:191-201. (Pubitemid 46090774)
57. Ujhazy P, Zaleskis G, Mihich E et al. Doxorubicin induces specific immune functions and cytokine expression in peritoneal cells. Cancer Immunol Immunother 2003; 52:463-472. (Pubitemid 36831368)
58. Usta Y, Ismailoglu UB, Bakkaloglu A et al. Effects of pentoxifylline in adriamycin-induced renal disease in rats. Pediatr Nephrol 2004; 19:840-843. (Pubitemid 39144764)
59. Szelenyi J. Cytokines and the central nervous system. Brain Res Bull 2001; 54:329-338. (Pubitemid 32288713)
60. Kreukels BP, Schagen SB, Ridderinkhof KR et al. Electrophysiological correlates of information processing in breast-cancer patients treated with adjuvant chemotherapy. Breast Cancer Res Treat 2005; 94:53-61. (Pubitemid 41416942)
61. Kreukels BP, Schagen SB, Ridderinkhof KR et al. Effects of high-dose and conventional-dose adjuvant chemotherapy on long-term cognitive sequelae in patients with breast cancer: an electrophysiologic study. Clin Breast Cancer 2006; 7:67-78. (Pubitemid 43862837)
62. Abraham J, Haut MW, Moran MT et al. Adjuvant chemotherapy for breast cancer: effects on cerebral white matter seen in diffusion tensor imaging. Clin Breast Cancer 2008; 8:88-91. (Pubitemid 351346234)
63. Saykin A, McDonald B, Ahles T et al. Altered brain activation following systemic chemotherapy for breast cancer: interim analysis from a prospective fMRI study. Presented at the 34th Annual Meeting of the International Neuropsychological Society, Boston, MA, 2006.
64. Ferguson RJ, McDonald BC, Saykin AJ et al. Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy. J Clin Oncol 2007; 25:3866-3870. (Pubitemid 47477262)
65. Silverman DHS, Dy CJ, Castellon SA et al. Altered frontocortical, cerebellar and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res Treat 2006; 103:303-311. (Pubitemid 46944511)
66. Stern Y. What is cognitive reserve? Theory and research applications of the reserve concept. J Int Neuropsychol Soc 2002; 8:448-460. (Pubitemid 34296102)
67. Miller AH, Ancoli-Israel S, Bower JR et al. Neuroendocrine-Immune Mechanisms of Behavioral Comorbidities in Patients With Cancer. J Clin Oncol 2008; 26:971-982. (Pubitemid 351409339)
68. Fishman D, Faulds G, Jeffery R et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102:1369-1376. (Pubitemid 28467565)
69. Caspi A, Sugden K, Moffitt TE et al. Influence of life stress on depression: Moderation by a polymorphism in the 5-HTT gene. Science 2003; 301:386-389. (Pubitemid 36877077)
70. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: Inflammation and the pathogenesis of depression. Trends Immunol 2006; 27:24-31. (Pubitemid 43083561)
71. Zorrilla EP, Luborsky L, McKay JR et al. The relationship of depression and stressors to immunological assays: A meta-analytic review. Brain Behav Immun 2001; 15:199-226. (Pubitemid 33070955)
72. Ridker PM, Rifai N, Stampfer MJ et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101:1767-1772. (Pubitemid 30213096)
73. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107:363-369. (Pubitemid 36158034)
74. Schmidt MI, Duncan BB, Sharrett AR et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): A cohort study. Lancet 1999; 353:1649-1652. (Pubitemid 29224520)
75. Browning LM, Krebs JD, Jebb SA. Discrimination ratio analysis of inflammatory markers: Implications for the study of inflammation in chronic disease. Metabolism 2004; 53:899-903. (Pubitemid 38829465)
76. Kuipers SD, Bramham CR. Brain-derived neurotrophic factor mechanisms and function in adult synaptic plasticity: New insights and implications for therapy. Curr Opin Drug Discov Devel 2006; 9:580-586. (Pubitemid 44378826)
77. Bianchi R, Brines M, Lauria G et al. Protective effect of erythropoietin and its carbamylated derivative in experimental Cisplatin peripheral neurotoxicity. Clin Cancer Res 2006; 12:2607-2612.